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ABSTRACT
Objective: To examine the correlates of the physical and psychosocial domains of
quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss
intervention trial.
Methods: Correlates of QOL and psychosocial functioning were examined in 692
overweight/obese breast cancer survivors at entry into a weight loss trial. QOL was
explored with three measures: Short-form 36 (SF-36); Impact of Cancer Scale (IOCv2);
and the Breast Cancer Prevention Trial (BCPT) Symptom Scales. Available data
included information on weight and physical activity, as well as demographic and
medical characteristics. Multivariate analyses were used to identify associations
adjusted for other characteristics.
Results: In multivariate analysis, younger age was associated with higher negative
impact scores (p < 0.0001). Hispanic, African-American and Asian women had higher
positive IOC impact scores compared to white non-Hispanic women (p < 0.01).
Increased number of co-morbidities was associated with lower physical and mental
QOL scores (p < 0.01). BMI was not independently associated with QOL measures.
Physical activity was directly associated with physical and mental QOL and IOC positive
impact, and inversely related to IOC negative impact and BCPT symptom scales.
Conclusions: QOL measures in breast cancer survivors are differentially associated with
demographic and other characteristics. When adjusted for these characteristics, degree
of adiposity among overweight/obese women does not appear to be independently
associated with QOL. Among overweight/obese breast cancer survivors, higher level of
physical activity is associated with higher QOL across various scales and dimensions.
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Introduction
Breast cancer diagnosis and treatment is associated with adverse health effects
in physical and psychosocial domains, and thus, can have a negative impact on quality
of life (QOL) [1]. Although most symptoms show improvement over time [2], some may
be long-term, lasting for up to 10 years after surgery and completion of treatment [3].
Among psychosocial correlates, depression and anxiety are often associated with
poorer QOL either as indicators [4] or determinants. Sleep problems and fatigue have
also been identified as being associated with poorer QOL [5], as well as weight gain
after treatment [6], and often these symptoms are interrelated [7].
In a systematic review, Chopra and Kamal [8] concluded that age, ethnicity, and
type of treatment influence different aspects of QOL. Similarly, differential effects of
treatment on QOL have been noted for race/ethnicity, and age [9-12]. Based on a
comprehensive literature review, Yanez et al. [13] concluded that Latina survivors
experience worse QOL than non-Latina whites, but White et al. [14] caution that racial
differences may be better explained by the variance in levels of engagement in healthy
behaviors. Concerns and adverse effects may be particularly notable for younger
survivors who report more adverse psychosocial and health outcomes [3, 15].
Premature menopause is thought to exacerbate the effects of treatment among these
younger women [16].
Obesity and weight gain, as indicated by high body mass index (BMI), has been
associated with worse QOL among breast cancer survivors [15, 17]. Post-diagnosis
physical activity has been identified as a protective factor that may mitigate common
side effects such as fatigue and weight gain [18] and improve overall QOL [19]. In a
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large randomized clinical trial of breast cancer survivors, participants who exercised at
least 150 minutes/week of moderate-paced walking reported significantly higher levels
of QOL independent of race/ethnicity [11].
The purpose of this analysis was to examine the correlates of QOL and
psychosocial functioning in overweight or obese breast cancer survivors using data
collected upon entry into a weight loss intervention trial. The multi-center Exercise and
Nutrition to Enhance Recovery and Good Health for You (ENERGY) study is the largest
weight loss study in this patient population to date, enrolling 692 overweight or obese
women who had been diagnosed and treated for early stage breast cancer [20]. Within
this large and well-characterized sample, different aspects of QOL were explored with
three measures: the Short-form 36 (SF-36) [21] as a general measure of physical and
mental QOL; Impact of Cancer Scale (IOCv2) to assess QOL and both positive and
negative aspects of cancer survivorship [10]; and the Breast Cancer Prevention Trial
(BCPT) Symptom Scales to evaluate side effects of treatment [22]. We hypothesized
that responses on the QOL measures would be differentially distributed across level of
adiposity, as well as age, race/ethnicity, cancer stage and treatment, number of comorbidities, and level of physical activity.
Methods
Participants and study procedures
A total of 692 overweight or obese breast cancer survivors were enrolled into a
randomized controlled trial of a weight loss intervention, the Exercise to Enhance
Recovery and Good Health for You (ENERGY) trial, at four sites (San Diego, CA;
Denver, CO; St. Louis, MO; and Birmingham, AL). Inclusion criteria were: age >21
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years; a history of breast cancer (stages I [≥1 cm], II, or III) diagnosed within the
previous five years; completion of initial therapies not including endocrine therapy; BMI
25-45 kg/m2; and ability to comply with study procedures. Exclusion criteria included:
history of malignancies other than initial breast cancer with the exception of nonmelanoma skin cancer, serious psychiatric illness, and any medical condition
substantially limiting moderate physical activity, such as severe orthopedic conditions.
The study was reviewed and approved by the Institutional Review Boards of all sites,
and participants provided written informed consent. A detailed description of the study
procedures and intervention has been published previously [20].
Measures
Demographic and other characteristics
Data included self-reported age, race/ethnicity, education level, marital status,
and medical history (including co-morbidities). Anthropometric measurements (height,
weight) were conducted by trained study staff using standard procedures and were
used to calculate BMI [23]. Medical record review was conducted to obtain information
on breast cancer diagnosis including stage and date of diagnosis and treatment and to
verify eligibility.
Physical activity was measured using the modified Godin Leisure-Time Exercise
Questionnaire (GLTEQ) which has been validated previously in cancer research [24].
The modified GLTEQ consists of three questions regarding the frequency and duration
of mild, moderate, and strenuous exercise performed during free time in a typical week.
Risk for depression was measured with the Center for Epidemiologic Studies
Depression Scale (CES-D). The CES-D is comprised of 20 items and assesses risk for
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depression in the general population [22]. Measures of internal consistency are high in
the general population (0.85) and in psychiatric samples (0.90). Test-retest correlations
are reported to be in the moderate range (0.45-0.70). Validity has been established
with other self-report measures, correlations with clinical ratings of depression, and by
construct validity [25]. It has also been used in other studies of cancer survivors [26].
Self-reported information on co-morbidities was collected with a questionnaire
modeled after the Self-Administered Co-morbidity Questionnaire [27]. Number of
reported co-morbidities (e.g., heart disease, hypertension, lung disease, diabetes, ulcer
or stomach disease, kidney disease, liver disease, anemia, depression, osteoarthritis,
back pain, rheumatoid arthritis, or other) was summed.
Psychosocial QOL measures
The SF-36 is a multi-purpose, brief health survey, which is used as a general
measure of physical and mental QOL [21, 28]. It is comprised of an 8-scale profile of
functional health and well-being scores as well as psychometrically-based physical and
mental health summary measures. There is considerable evidence for the reliability of
the SF-36 (Cronbach’s α>0.85, reliability coefficient >0.75) [28, 29]. It has been used
extensively with breast cancer survivors [5, 6, 26].
The BCPT Symptom Scales have been used to measure concurrent and late
side effects of medical interventions to prevent and treat breast cancer [22]. Factor
analysis with this instrument [22] has revealed eight symptom clusters corresponding to
physical symptoms associated with cancer treatment, chemoprevention, menopause,
and normal aging: hot flashes, nausea, bladder control, vaginal problems,
musculoskeletal pain, cognitive problems, weight problems, and arm problems.
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The IOC was developed specifically to measure the impact of cancer on aspects
of QOL in long term survivors (i.e. > 5 years since diagnosis) [10]. Recent refinement of
this instrument in a large sample of long-term breast cancer cancer survivors (ref 10)
yielded a factor structure relating IOC items to psychosocial impact domains that
exhibited high factor loadings (factor-item correlations of 0.59-0.94) and high internal
consistency (Cronbach’s α=0.76-0.89). The scales consist of a Positive Impact
Summary Scale with four subscales (altruism and empathy, health awareness, meaning
of cancer, and positive self-evaluation), a Negative Impact Summary Scale with four
subscales (appearance concerns, body change concerns, life interferences, and worry),
and subscales for Employment and Relationship Concerns.
Statistical analysis
For the five overall QOL outcome measures (summary scores for physical and
mental QOL, IOC positive and negative impact scales, and mean severity averaged
across all 18 symptoms on the BCPT questionnaire), bivariate analyses were used to
examine associations with the a priori hypothesized influencing variables (BMI, age,
race/ethnicity, cancer stage and treatment, number of co-morbidities, and level of
physical activity) and exploratory variables (education, marital status, and time since
diagnosis). We hypothesized that greater degree of adiposity (higher BMI), younger
age, higher stage, chemotherapy, and number of co-morbidities would be associated
with worse physical and mental QOL, higher IOC negative impact, and greater BCPT
symptoms. We also hypothesized that higher physical activity would be inversely
associated with these measures.
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Continuous variables (age, BMI, number of co-morbidities, weekly hours of
moderate/vigorous activity, and CES-D score) were modeled in continuous ANOVA.
Categorical variables (race/ethnicity, cancer stage, chemotherapy, endocrine therapy,
education, marital status) were compared using categorical ANOVA where the first
category was the referent. Implementing a conservative strategy, we used a
significance level of alpha = 0.01 for the bivariate models, and p ≤ 0.05 in the
multivariate model, without further adjustment for multiple comparisons. All tests were
two-sided.
Multivariate models for four of the main outcomes (physical and mental QOL and
IOC positive and negative impact scale) used regression models to examine
relationships between the predictors jointly and outcomes. The multivariate analyses
included all variables that were a priori hypothesized predictors, as well as the 8 BCPT
symptom clusters, but did not include the exploratory variables. Dependent variables
were log transformed to reduce skew in their distributions.
We also evaluated the four subscales each from the IOC Positive and Negative
Impact Scales separately. We set significance at p < 0.01 for the subscale analyses.
Analyses were conducted using SAS version 9.3 (Cary, NC).
Results
Participants were 692 overweight or obese breast cancer survivors with a mean
(SD) age of 56 (9) years at enrollment. Characteristics of the study sample and
distribution of scores across the QOL measures are shown in Tables 1 and 2. The
majority of the sample was non-Hispanic white, and BMI at study entry was 31.4 (4.7)
kg/m2. On average, time since diagnosis was 2.7 years (range 0.25-5.8 years). A
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majority of the women had been diagnosed with stage II cancer (52%), and 30% and
18% had stage I and stage III cancer, respectively.
In bivariate analysis, responses on the QOL measures were differentially
distributed across categories of demographic characteristics, as shown in Table 1. QOL
measures differed across age, BMI, and race/ethnicity categories. Compared to white,
non-Hispanic participants, Hispanic, African-American and Asian participants all
reported higher scores on the IOC positive impact scale (p < 0.01). Responses on the
QOL measures also were differentially distributed across categories of medical and
cancer-related factors, as shown in Table 2. Having more co-morbidities was
associated with lower physical and mental QOL scores (p < 0.01).
Differential responses on the QOL measures across physical activity and CES-D
score categories are shown in Table 3. Being moderately active, as is recommended
for weight management [30], was associated with better scores on the physical and
mental QOL scales (p < 0.01), and a dose-response effect was observed. Higher level
of physical activity was associated with lower scores on the IOC negative impact scale
(p < 0.01) and with lower scores on the BCPT symptoms scales (p < 0.01). The reverse
was true for those who had higher scores (≥16) on the CES-D. Those at higher risk for
depression had lower scores on physical and mental QOL and higher scores on the
BCPT symptom scales (p < 0.01).
Table 4 shows the associations for the a priori hypothesized variables when
adjusted for other influencing variables in the multivariate models. Younger age was
associated with higher IOC negative impact scale (p < 0.0001). Hispanic, AfricanAmerican and Asian women had higher scores on the IOC positive impact scale
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compared to white, non-Hispanic women, and African-American women scored lower
on the IOC negative impact scale (p < 0.01). Number of co-morbidities and several
BCPT symptom clusters were associated with lower physical and mental QOL (p <
0.02), when adjusted for other variables.
Contrary to our hypothesis, BMI was not independently associated with any of
the QOL measures in the multivariate models. As hypothesized, level of physical
activity was associated with physical and mental QOL (p < 0.01). Women with higher
levels of depressive symptoms on the CES-D had significantly lower physical QOL,
lower IOC positive impact and higher IOC negative impact scores (p <0.001).
As shown in Table 4, the BCPT symptom scale for nausea was inversely
associated with both physical and mental QOL (p < 0.01). The BCPT scale for bladder
control was inversely associated with mental QOL, and the musculoskeletal pain scale
was inversely associated with physical and mental QOL (p < 0.02). Cognitive problems
were inversely associated with mental QOL, and directly associated with both IOC
positive and negative impact scores. The BCPT symptom scale for weight problems
was inversely associated with mental QOL and directly associated with the IOC
negative impact scores (p < 0.01). The BCPT arm problems scale was inversely
associated with physical QOL scores, meaning lower severity of arm problems was
associated with better physical QOL scores, and directly associated with the IOC
negative impact scale (p < 0.001). Two of the symptom scales (vasomotor and vaginal
problems) were not significantly associated with any of the QOL outcomes.
Associations with the subscales of the IOC negative and positive impact score
also were examined (data not shown), and cancer stage was directly associated with
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scores for each negative impact subscale (p < 0.01). In contrast, age and AfricanAmerican ethnicity were inversely associated with every subscale score. Age was
inversely associated with altruism and meaning of cancer subscale scores. AfricanAmerican, Asian and Hispanic race/ethnicity were all directly associated with health
awareness and positive self-concerns subscales. In addition, being African-American
was associated with greater meaning of cancer, while being Asian was associated with
altruism. Chemotherapy was directly associated with scores for all four IOC positive
impact subscales (p < 0.01 for all).
Discussion
We found that various dimensions and measures of QOL in breast cancer
survivors are differentially associated with demographic and medical characteristics.
After adjusting for these characteristics, contrary to our hypotheses, degree of adiposity
had no relationship to any of the QOL outcomes in the multivariable models, although
BMI was inversely associated with physical (but not mental) QOL when unadjusted for
other influencing variables. However, we found that among overweight or obese breast
cancer survivors, higher level of physical activity correlates with higher mental and
physical QOL and does so in a dose-dependent manner.
This analysis presents a multifaceted approach to examining QOL in a large and
geographically-diverse sample of overweight or obese breast cancer survivors. By
utilizing several different measurement constructs, this study provides a global
examination of the psychosocial and physical QOL associations in this target
population. In particular, this is the first study, to our knowledge, to have used the IOC
in shorter-term breast cancer survivors, along with the SF-36 and the BCPT symptom
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scales. In addition to the large sample, the diversity of the sample also allowed analysis
of findings for various subgroups, such as older versus younger survivors or those with
different racial/ethnicity and cancer characteristics.
The characteristics that were found to impact QOL in the current study can be
compared to those reported in other studies with breast cancer survivors, and confirm
and expand upon what has been observed in other reports. Using the SF-36, Bowen et
al. [9] concluded that participants in the HEAL study were doing relatively well two years
after diagnosis, even though some racial/ethnic and socioeconomic differences were
identified as important determinants of QOL. Utilizing the BCPT Symptom Scales,
Ganz et al. [1] noted that even though overall functioning improved after breast cancer
treatment, those who received chemotherapy reported more severe physical symptoms
such as vaginal and weight problems.
In this study, age at diagnosis and non-white race/ethnicity (Hispanic, AfricanAmerican or Asian) were identified as independently associated with QOL in breast
cancer survivors, with younger women experiencing more negative impact from the
cancer and non-white women noting more meaning and positive impact from the cancer
experience. This is consistent with other studies in the literature, although this study is
notable for assessing these issues in a group of women earlier in the post-treatment
phase of survivorshipAlthough younger participants noted some positive outcomes from
their experience on the IOC measure (i.e., becoming more health aware, valuing their
relationships more), our results suggest that their overall outlook on body changes was
more negative, and they reported more health-related worries and treatment-related
symptoms. This observation held true in IOC subscale analysis as well. In another
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sample of breast cancer survivors, Crespi et al. [11] also found younger women to have
somewhat higher scores on both positive and negative IOC scores, and results from
previous studies indicate that survivors <50 years of age report concerns about
premature menopause and infertility, physiologic symptoms such as night sweats and
hot flashes, weight gain, and adverse psychosocial outcomes, such as depressive
symptoms [15, 16]. Future studies that focus on identifying effective strategies to
improve QOL in this vulnerable group of survivors are clearly warranted.
Racial/ethnic minority participants reported higher IOC positive and negative
impact scores which may indicate willingness to see cancer as a positive life challenge,
such as having more health awareness and positive self-concerns as identified by IOC
subscale analysis. Other studies have noted greater meaning and personal growth
among African-American breast cancer survivors [31, 32], and better QOL. Different
levels of QOL for survivors with diverse racial and ethnic backgrounds have been
identified in prior studies [13].
The association between degree of adiposity (reflected in the BMI) and better
physical QOL in the bivariate analysis did not remain significant in the multivariate
model, although at enrollment in this study, none of the participants was in the healthy
weight range. In another sample of breast cancer survivors, higher BMI was associated
with higher IOC negative impact and subscales [11], but that observation was not
adjusted for other influencing factors as in the present study. There is evidence in the
literature that maintaining a healthy weight is an independent factor for better prognosis
of breast cancer [33, 34], as well as for better overall physical functioning and
management of treatment side effects such as sleep and mood problems [6]. However,
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results of this analysis suggest that in overweight or obese women, co-morbidities and
other factors are crucial determinants of QOL.
As in the present study, Ashing-Giwa and Lim [35] found that having fewer comorbidities were related to better mental and physical QOL in a diverse group of breast
cancer survivors. This is an important finding because it suggests that overweight or
obese breast cancer survivors who can lose enough weight to impact co-morbidities,
even if they do not achieve an optimal weight, may improve QOL. Ganz et al. [1] found
that even though physical and social functioning improves after treatment, physical
symptoms persist for those who have received chemotherapy for up to a year.
Similarly, in the current study, participants indicated experiencing lower mental and
physical QOL in association with a myriad of symptoms such as nausea, bladder control
issues, and musculoskeletal and arm problems. That these factors are contributing to
lower mental and physical QOL is an important finding, and attention to symptom
control could be important for improving QOL outcomes.
Multivariate models in this study revealed that more physical activity in these
overweight or obese women was related to better overall QOL, having a more positive
outlook on life, as well as having fewer health-related worries and treatment-related
symptoms. In fact, our observations suggest that any amount of exercise is better than
none. In contrast, higher depressive symptomatology scores were associated with
lower physical QOL scores, as well as lower positive impact and higher negative impact
IOC scores, as previously observed in this target population [11]. Although this analysis
uses cross-sectional data that cannot imply causality, previous interventions have
shown that exercise has positive impact on overall QOL [36] and also depressive
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symptoms [37, 38] and fatigue [39]. Regular physical activity after breast cancer
diagnosis and treatment also may mitigate common side effects of adjuvant therapy,
such as weight gain and fatigue [36], depression, reduced QOL, as well as decreased
muscular strength [40].
Results of this study present important evidence of symptom burden following
treatment in overweight or obese breast cancer survivors. However, this study also has
limitations. Even though the large sample size allowed for subgroup analysis, the study
sample was nonetheless largely homogeneous, so results may not be entirely
representative of the general population of breast cancer survivors. Nevertheless, most
breast cancers are diagnosed in overweight or obese women, and our sample had more
diversity than most other studies in this research area. It is important to examine these
constructs in an even more diverse sample of breast cancer survivors, particularly
among those across an even wider range of BMI, including lean women. Additionally,
we have not addressed all potential confounding influences, such as income [35],
location of treatment (e.g., academic centers, community- or hospital-based practices),
or rural vs. urban environment. Finally, the relationship between depression and QOL is
not straightforward, and future research should examine the impact of these variables
on QOL. Future research is needed to examine this complex association in cancer
survivors to determine if depression is an indicator or determinant of QOL.
These baseline findings set the stage for the longitudinal evaluation of QOL
outcomes in this study sample. In future analyses we can examine whether increased
physical activity and weight loss have a positive impact on QOL and improve long term
functionality in this group of overweight or obese breast cancer survivors.
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Table 1. Quality of life (QOL) measures within demographic and anthropometric categories (N = 692)a

N

QOL
Physical

QOL
Mental

IOC Positive
Impact Scale

IOC Negative
Impact Scale

BCPT
Symptom
Scales

<50

173

70.4 (19.5)

73.4 (19.2)

3.9 (0.5)*

2.9 (0.8)*

2.1 (0.6)*

50-64

372

71.8 (18.4)

76.0 (18.0)

3.8 (0.6)*

2.7 (0.7)*

2.1 (0.5)*

≥65

147

67.7 (17.8)

77.2 (16.4)

3.7 (0.5)*

2.4 (0.7)*

1.9 (0.5)*

25-29.99

285

72.3 (17.9)*

75.9 (17.9)

3.8 (0.6)

2.7 (0.7)

2.0 (0.5)

30-34.99

243

70.5 (18.8)*

74.7 (18.5)

3.8 (0.6)

2.6 (0.7)

2.0 (0.5)

35-45

164

67.6 (19.2)*

76.3 (17.5)

3.8 (0.6)

2.6 (0.7)

2.1 (0.6)

White, non-Hispanic

547

70.8 (17.7)

75.9 (17.3)

3.8 (0.5)

2.7 (0.7)

2.0 (0.5)

Hispanic

46

68.9 (19.2)

70.3 (21.5)

4.0 (0.5)*

2.8 (0.7)

2.1 (0.6)

African-American

71

67.9 (24.3)

75.2 (21.1)

4.0 (0.6)*

2.5 (0.8)

2.2 (0.6)

Asian

11

76.8 (13.9)

82.1 (11.5)

4.3 (0.3)*

2.8 (0.6)

1.7 (0.3)

Mixed/other

15

74.1 (18.4)

76.3 (17.7)

3.9 (0.6)

2.7 (0.7)

1.9 (0.4)

Not a college graduate

282

70.6 (18.5)

76.0 (17.5)

3.9 (0.5)*

2.6 (0.7)

2.1 (0.5)

College graduate

410

70.5 (18.7)

75.3 (18.3)

3.7 (0.6)*

2.7 (0.7)

2.0 (0.6)

Married/partnered

463

72.0 (17.7)

77.1 (17.5)

3.8 (0.6)

2.7 (0.7)

2.1 (0.5)

Not married or partnered

228

67.6 (20.1)*

72.5 (20.4)*

3.8 (0.6)

2.7 (0.8)

2.0 (0.5)

Age at enrollment (yrs)

Body mass index (kg/m2)

Race/ethnicity

Education

Marital status

a

Values shown are mean (SD).

25
* p < 0.01; continuous variables (age and body mass index) were modeled in continuous ANOVA, and categorical variables were
compared using categorical ANOVA where the first category was the referent.
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Table 2. Quality of life (QOL) measures within medical and cancer-related categories (N = 692)a

QOL Mental

IOC Positive
Impact Scale

IOC Negative
Impact Scale

BCPT
Symptom
Scales

66.1 (21.1)*

70.5 (21.2)*

3.9 (0.6)

2.7 (0.7)

2.1 (0.6)

325

69.5 (18.9)*

75.0 (17.6)*

3.8 (0.6)

2.7 (0.7)

2.1 (0.5)

291

72.9 (17.2)*

77.5 (17.2)*

3.8 (0.6)

2.6 (0.7)

2.0 (0.6)

I

210

73.3 (17.5)

77.2 (17.6)

3.7 (0.6)

2.5 (0.7)

2.0 (0.5)

II

358

70.7 (18.8)

75.4 (18.0)

3.8 (0.6)*

3.0 (0.7)*

2.1 (0.6)

III

124

65.4 (18.8)*

73.3 (18.4)

3.9 (0.5)

2.9 (0.7)*

2.1 (0.5)*

No

165

73.5 (17.5)

76.6 (18.3)

3.6 (0.6)

2.5 (0.7)

1.9 (0.5)

Yes

527

69.6 (18.8)

75.3 (17.9)

3.9 (0.5)*

2.7 (0.7)*

2.1 (0.6)*

None

179

69.0 (19.6)

74.2 (19.3)

3.8(0.6)

2.8 (0.8)

2.0 (0.5)

Anti-estrogen only

147

71.5 (20.4)

75.4 (17.5)

3.9 (0.5)

2.7 (0.7)

2.1 (0.6)

Aromatase inhibitor

366

70.9 (17.3)

76.3 (17.5)

3.8 (0.6)

2.6 (0.7)

2.1 (0.6)

None

253

75.7 (16.2)*

78.2 (16.0) *

3.9 (0.5)

2.6 (0.7)

2.0 (0.6)*

1

240

70.5 (18.2)*

76.2 (17.3)*

3.7 (0.6)

2.7 (0.7)

2.0 (0.5)*

2

119

67.5 (18.4)*

74.0 (18.6)*

3.8 (0.6)

2.6 (0.7)

2.9 (0.5)*

3 or more

80

59.0 (21.1)*

67.7 (22.2)*

3.8 (0.6)

2.7 (0.8)

2.2 (0.6)*

N

QOL
Physical

<1 year

76

1-2.9 years
≥3 years

Time since diagnosis

Cancer stage

Chemotherapy

Endocrine therapy

b

Co-morbidities

a

Values shown are mean (SD).
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b

Co-morbidities assessed are current treatment for heart disease, hypertension, lung disease, diabetes, ulcer or stomach disease,
kidney disease, liver disease, anemia, depression, osteoarthritis, back pain, rheumatoid arthritis and other conditions.
* p < 0.01, continuous variables were modeled in continuous ANOVA, and categorical variables (cancer stage, chemotherapy, and
endocrine therapy) were compared using categorical ANOVA where the first category was the referent.
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Table 3. Quality of life (QOL) measures within strata of behavioral and psychosocial covariates (N = 692)a

N

QOL
Physical

QOL
Mental

IOC Positive
Impact Scale

IOC Negative
Impact Scale

BCPT
Symptom
Scales

None

284

65.9 (19.6)*

72.3 (19.0)*

3.8 (0.6)

2.7 (0.7)*

2.1 (0.5)*

0.1-0.9

70

69.0 (18.8)*

73.8 (17.0)*

3.8 (0.5)

2.9 (0.7)*

2.1 (0.6)*

1-2.9

208

73.6 (16.6)*

77.1 (16.7)*

3.8 (0.6)

2.6 (0.7)*

2.0 (0.5)*

3 or more

130

76.6 (16.8)*

81.3 (16.8)*

3.9 (0.6)

2.6 (0.7)*

1.9 (0.6)*

Not depressed (0-15)

555

73.9 (16.6)*

81.0 (12.6)*

3.8 (0.6)

2.5 (0.6)*

1.9 (0.5)*

At risk for depression (≥16)

137

57.1 (20.1)*

53.7 (19.8)*

3.8 (0.6)

3.3 (0.8)*

2.5 (0.5)*

Moderate/vigorous activity, hrs/wk

CES-D score

a

Values shown are mean (SD).
*p < 0.01.

29
Table 4. Multivariate models for quality of life (QOL) measures in overweight/obese breast cancer survivors (N = 692) a
IOC Positive
IOC Negative
QOL Physical
QOL Mental
Impact Scale
Impact Scale
R2=0.43
R2=0.30
R2=0.11
R2=0.39
ß
ß
ß
ß
Coefficient p Value Coefficient p Value Coefficient p Value Coefficient p Value
Age

-.001

.55

.002

.15

-.004

.12

-.011

<.0001

Body mass index

-.003

.20

.003

.28

-.000

.95

-.009

.08

Race/ethnicity
African-American
Asian
Hispanic

.002
.018
-.003

.94
.81
.94

-.027
.018
-.056

.50
.84
.22

.269
.538
.233

.0002
.001
.006

-.396
.173
.090

<.0001
.33
.32

Cancer stage

-.027

.10

-.013

.49

-.003

.92

.125

.0008

Chemotherapy

.022

.40

.037

.22

.233

<.0001

.023

.69

Any endocrine therapy

.032

.16

.029

.28

.046

.34

-.092

.08

No. of co-morbidities

-.040

<.0001

-.032

.006

-.012

.58

.024

.30

Moderate/vigorous activity

.012

.006

.014

.01

.010

.29

-.002

.82

CES-D Score*

-.009

<.0001

x

x

-.012

.001

.031

<.0001

Hot flashes

-.005

.55

.002

.84

.015

.44

.010

.63

Nausea

-.083

.002

-.086

.005

-.061

.27

.031

.60

Bladder control

.011

.36

-.028

.05

.003

.91

.021

.45

Vaginal problems

.013

.12

.006

.53

.001

.94

.021

.28

Musculoskeletal pain

-.128

<.0001

-.032

.02

-.001

.96

.048

.09

Cognitive problems

-.016

.23

-.124

<.0001

.081

.004

.064

.04

Weight problems

-.006

.54

-.041

.0009

-.012

.60

.112

<.0001

Arm problems

-.046

.001

.008

.60

.002

.95

.088

.006

BCPT symptom clusters
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a

Values shown are ß coefficients and p values for associations with each of the four outcomes, when controlled for all variables
tabulated. Quality of life outcomes were log transformed
* CES-D score was omitted as a predictor for QOL Mental because of high correlation between the two (rho = -0.72).

